Cancer and blood coagulation.
In human patients, blood coagulation disorders often associate with cancer, even in its early stages. Recently, in vitro and in vivo experimental models have shown that oncogene expression, or inactivation of tumour suppressor genes, upregulate genes that control blood coagulation. These studies suggest that activation of blood clotting, leading to peritumoral fibrin deposition, is instrumental in cancer development. Fibrin can indeed build up a provisional matrix, supporting the invasive growth of neoplastic tissues and blood vessels. Interference with blood coagulation can thus be considered as part of a multifaceted therapeutic approach to cancer.
Boccaccio
C
C
Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, Str. Prov. 142, 10060 Candiolo, Italy. carla.boccaccio@ircc.it
Medico
E
E
D000818:Animals; D001777:Blood Coagulation / Q000235:genetics*; D051546:Cyclooxygenase 2 / Q000235:genetics; D005337:Fibrin / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006487:Hemostasis / Q000235:genetics; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D008957:Models, Genetic; D009369:Neoplasms / Q000098:blood supply / Q000235:genetics*; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics
D008565:Membrane Proteins; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D005337:Fibrin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human